Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0360220120530091352
Journal of the Korean Ophthalmological Society
2012 Volume.53 No. 9 p.1352 ~ p.1356
Intravitreal Bevacizumab Injection for Choroidal Neovascularization Secondary to Laser Photocoagulation for Central Serous Chorioretinopathy
Jung Jong-Hyun

Moon Kun
Kim Kwang-Soo
Kim Yu-Cheol
Abstract
Purpose: To report a case of intravitreal bevacizumab injection for choroidal neovascularization following direct laser photocoagulation for central serous chorioretinopathy.

Case summary: A 44-year-old male patient with an 8-month history of metamorphopsia in his left eye visited our clinic and was diagnosed with central serous chorioretinopathy after performing refraction, fundus examination, fluorescein angiography (FAG) and optical coherence tomography (OCT). After 1 month, laser photocoagulation of the leaking point observed on the FAG was performed. After 8 weeks following laser photocoagulation, visual acuity was reduced to 0.4, subretinal hemorrhage accompanied by choroidal neovascularization was observed on FAG and OCT, and an intravitreal bevacizumab injection was administered. After 4 weeks following the injection, macular edema and subretinal hemorrhage decreased, visual acuity increased to 1.0 and was maintained properly. However, after 2 years, the central serous chorioretinopathy recurred and after 3 months, healed spontaneously.

Conclusions: Intravitreal bevacizumab injection is a safe and effective treatment for secondary choroidal neovascularization occurring after direct laser photocoagulation for central serous chorioretinopathy. In addition, a single treatment can maintain the patient¡¯s status with no recurrence of choroidal neovascularization over a long-term period.
KEYWORD
Bevacizumab, Central serous chorioretinopathy, Choroidal neovascularization
FullTexts / Linksout information
 
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø